Gregory J Riely
#116,244
Most Influential Person Now
Researcher
Gregory J Riely's AcademicInfluence.com Rankings
Gregory J Rielyengineering Degrees
Engineering
#3537
World Rank
#4631
Historical Rank
Electrical Engineering
#798
World Rank
#866
Historical Rank
Gregory J Rielycomputer-science Degrees
Computer Science
#4544
World Rank
#4794
Historical Rank
Computational Linguistics
#457
World Rank
#464
Historical Rank
Machine Learning
#927
World Rank
#940
Historical Rank
Artificial Intelligence
#1146
World Rank
#1166
Historical Rank
Download Badge
Engineering Computer Science
Gregory J Riely's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Gregory J Riely Influential?
(Suggest an Edit or Addition)Gregory J Riely's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005) (3427)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) (3079)
- Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients (2017) (2165)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) (2120)
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers (2013) (2004)
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) (1619)
- OncoKB: A Precision Oncology Knowledge Base. (2017) (1317)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005) (1226)
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. (2012) (1194)
- Crizotinib in ROS1-rearranged non-small-cell lung cancer. (2014) (1089)
- Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018) (908)
- Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (875)
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011) (875)
- Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases (2011) (833)
- Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (2006) (807)
- Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology (2017) (805)
- Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (734)
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (2006) (709)
- Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011) (635)
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. (2014) (617)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. (2011) (600)
- HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. (2012) (598)
- Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. (2019) (596)
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. (2018) (595)
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010) (570)
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. (2015) (555)
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011) (547)
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma (2008) (534)
- KRAS mutations in non-small cell lung cancer. (2009) (530)
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. (2016) (491)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. (2019) (490)
- New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. (2013) (479)
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013) (478)
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers (2012) (464)
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. (2018) (451)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. (2021) (423)
- Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer (2014) (421)
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 (2012) (421)
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) (419)
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. (2017) (412)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. (2018) (411)
- Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (411)
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) (397)
- Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer (2006) (393)
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design (2011) (386)
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials (2009) (386)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. (2016) (382)
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. (2016) (373)
- Non-Small Cell Lung Cancer, Version 6.2015. (2015) (373)
- Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. (2014) (360)
- Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis (2008) (359)
- Targeting ALK: Precision Medicine Takes on Drug Resistance. (2017) (333)
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. (2017) (316)
- Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (313)
- Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. (2016) (312)
- Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (2015) (312)
- Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. (2009) (304)
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
- Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. (2016) (297)
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus (2007) (297)
- Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (2013) (285)
- Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (284)
- Non-small cell lung cancer. (2012) (277)
- Non-small cell lung cancer. Clinical practice guidelines in oncology. (2004) (269)
- Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma (2008) (263)
- Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. (2011) (255)
- Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing (2011) (242)
- Non-small cell lung cancer, version 2.2013. (2013) (234)
- Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer (2017) (222)
- Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. (2006) (217)
- Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. (2011) (215)
- Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers (2018) (211)
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling (2011) (210)
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (2014) (209)
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. (2019) (209)
- Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration (2019) (206)
- EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer (2019) (201)
- Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. (2020) (197)
- Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. (2015) (195)
- Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease (2014) (188)
- PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers (2018) (186)
- EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. (2008) (185)
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 (2019) (184)
- Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. (2019) (177)
- COVID-19 in patients with lung cancer (2020) (174)
- Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance (2018) (173)
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. (2019) (170)
- Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). (2012) (168)
- Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib (2008) (166)
- Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. (2014) (164)
- Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas (2009) (162)
- Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib (2012) (160)
- Non-small cell lung cancer, version 1.2015. (2014) (154)
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer (2020) (153)
- Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib (2015) (149)
- Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (147)
- Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker (2012) (141)
- Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas (2013) (139)
- Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. (2020) (131)
- Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib (2011) (129)
- A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer (2015) (129)
- Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. (2013) (128)
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations (2011) (126)
- Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation (2014) (126)
- Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (126)
- SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas (2019) (125)
- Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. (2021) (124)
- A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma (2012) (124)
- Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens (2011) (120)
- An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer (2017) (118)
- Comparison of patterns of relapse in thymic carcinoma and thymoma. (2008) (115)
- Acquired Resistance to KRASG12C Inhibition in Cancer. (2021) (114)
- Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib (2019) (113)
- Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. (2008) (113)
- Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. (2018) (113)
- Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer (2010) (112)
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. (2019) (108)
- Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). (2016) (106)
- Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers (2014) (105)
- The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
- Non-small cell lung cancer. (2010) (103)
- Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer (2007) (101)
- Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. (2015) (100)
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. (2021) (100)
- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013) (100)
- KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma (2013) (99)
- HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation (2012) (99)
- Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. (2014) (98)
- Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. (2016) (97)
- Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. (2014) (94)
- Placental protein 14 functions as a direct T-cell inhibitor. (1999) (94)
- Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers (2018) (94)
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. (2021) (94)
- Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency (2016) (93)
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients (2021) (91)
- Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes (2014) (89)
- A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. (2018) (89)
- Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers (2013) (88)
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer (2010) (88)
- Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma (2011) (87)
- Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. (2016) (87)
- Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report (2010) (86)
- Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas (2015) (85)
- Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer (2021) (85)
- Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. (2019) (84)
- Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene. (1994) (83)
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation (2020) (83)
- Diverse alterations associated with resistance to KRAS(G12C) inhibition (2021) (82)
- Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib (2011) (81)
- Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. (2018) (79)
- Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers (2019) (79)
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. (2022) (77)
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. (2016) (76)
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans (2011) (75)
- Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. (2020) (74)
- Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. (2014) (73)
- Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (2014) (72)
- A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers (2016) (71)
- The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer (2020) (70)
- EGFR: The Paradigm of an Oncogene-Driven Lung Cancer (2015) (67)
- Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). (2013) (64)
- Chemotherapy definitions and policies for thymic malignancies. (2011) (64)
- Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations (2010) (63)
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. (2020) (60)
- Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer (2007) (60)
- Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. (2019) (60)
- Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR‐Mutated Lung Cancers (2019) (60)
- Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib (2011) (59)
- Germline EGFR T790M mutation found in multiple members of a familial cohort. (2014) (58)
- Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? (2014) (57)
- Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations (2016) (57)
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (57)
- Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. (2011) (56)
- Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). (2018) (55)
- Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas (2012) (55)
- Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. (2009) (55)
- Thymomas and thymic carcinomas (2013) (54)
- A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. (2007) (54)
- Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. (2013) (54)
- Negative Regulation of T Cell Activation by Placental Protein 14 Is Mediated by the Tyrosine Phosphatase Receptor CD45* (2003) (53)
- KRAS mutations: an old oncogene becomes a new predictive biomarker. (2008) (51)
- Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. (2013) (50)
- Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. (2014) (49)
- Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging (2014) (49)
- Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach (2019) (48)
- Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. (2011) (48)
- Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies (2010) (47)
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (47)
- Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis (2015) (47)
- EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. (2006) (46)
- Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors (2017) (46)
- ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. (2012) (44)
- Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. (2016) (44)
- Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. (2016) (43)
- A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds. (2001) (43)
- Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. (2015) (42)
- Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. (2011) (41)
- 1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY. (2014) (41)
- 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation (2021) (40)
- Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer (2012) (39)
- Induction therapy for locally advanced thymoma. (2010) (38)
- A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. (2012) (38)
- PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC). (2017) (37)
- Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer (2021) (37)
- Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer (2019) (37)
- Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study (2019) (36)
- Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. (2019) (36)
- YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics (2018) (35)
- Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers (2019) (35)
- A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. (2020) (34)
- Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer (2008) (34)
- A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR‐Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib (2017) (34)
- 1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1. (2014) (34)
- First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC). (2018) (33)
- Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (2012) (33)
- Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer (2015) (33)
- First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. (2015) (32)
- Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. (2017) (32)
- OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer (2018) (31)
- Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial (2016) (31)
- Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. (2018) (31)
- Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. (2020) (31)
- Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers (2013) (31)
- Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions (2019) (30)
- Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients (2017) (30)
- Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors. (2020) (30)
- Failure Patterns Relative to Radiation Treatment Fields for Stage II–IV Thymoma (2014) (29)
- Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions (2021) (29)
- Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial (2007) (28)
- Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC (2018) (28)
- LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) (2014) (27)
- Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade. (2020) (27)
- Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases (2018) (26)
- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) (2020) (26)
- The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. (2008) (25)
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion (2011) (25)
- Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. (2017) (24)
- Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers. (2019) (24)
- SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. (2021) (23)
- P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC (2018) (23)
- Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas. (2019) (23)
- BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL (2014) (23)
- A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). (2013) (23)
- MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB (2018) (23)
- OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 (2018) (22)
- A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (2015) (21)
- Incorporation of crizotinib into the NCCN guidelines. (2011) (21)
- Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. (2016) (21)
- Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. (2018) (21)
- MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions (2020) (21)
- Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. (2017) (21)
- What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer. (2017) (20)
- Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers (2019) (19)
- NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer (2014) (19)
- EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. (2008) (19)
- Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 (2014) (19)
- MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. (2016) (19)
- OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations (2021) (19)
- Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. (2017) (19)
- Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. (2010) (18)
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline (2022) (18)
- Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy? (2008) (18)
- Focal Localization of Placental Protein 14 Toward Sites of TCR Engagement1 (2002) (18)
- Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation (2011) (17)
- P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789 (2018) (17)
- Ef fi cacy of Platinum/Pemetrexed Combination Chemotherapy in ALK -Positive NSCLC Refractory to Second-Generation ALK Inhibitors (2020) (17)
- Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. (2018) (17)
- Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) andALKkinase domain mutations (2018) (17)
- Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. (2021) (17)
- Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma. (2010) (16)
- The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma (2013) (16)
- Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group (2017) (16)
- Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
- KRAS mutational testing in the selection of patients for EGFR-targeted therapies. (2008) (15)
- Non – Small Cell Lung Cancer, Version 3.2022 (2022) (15)
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline (2022) (15)
- Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations? (2017) (15)
- Association of outcomes and co-occuring genomic alterations in patients with KRAS-mutant non-small cell lung cancer. (2016) (15)
- MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer (2017) (15)
- [Chemotherapy definitions and policies for thymic malignancies]. (2014) (15)
- Phase II trial of bortezomib in KRAS G12D mutant lung cancers. (2015) (15)
- Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer (2021) (15)
- Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. (2018) (14)
- Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. (2006) (14)
- Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC) (2008) (14)
- MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer (2017) (13)
- Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers. (2016) (13)
- Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC). (2017) (13)
- Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations. (2013) (13)
- A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. (2015) (13)
- Molecular on/off switch. (2006) (12)
- Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. (2021) (12)
- Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. (2021) (12)
- Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas (2015) (12)
- Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. (2009) (12)
- A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers. (2015) (12)
- Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer (2021) (11)
- Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
- alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14. (2000) (11)
- Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. (2014) (11)
- CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. (2020) (11)
- RET-rearranged lung cancers: Immunophenotype and response to immunotherapy. (2018) (11)
- Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab (2013) (11)
- Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13. (2013) (11)
- Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). (2019) (10)
- EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC (2005) (10)
- Predictive Biomarkers and Personalized Medicine Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T 790 M Mutation Using a Locked Nucleic Acid-Based Assay (2011) (10)
- Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell free DNA over cell pellet genomic DNA for molecular profiling. (2021) (10)
- Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer. (2006) (10)
- Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC). (2011) (10)
- A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. (2009) (10)
- Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). (2010) (10)
- Specifying the True- and False-Positive Rates in Basket Trials. (2017) (10)
- Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. (2017) (10)
- Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? (2014) (10)
- A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers. (2019) (10)
- A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers. (2017) (10)
- 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins) (2020) (9)
- KRAS Mutations (2010) (9)
- Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. (2020) (9)
- Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium (2016) (9)
- Structural, biochemical, and clinical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, (225er1)) (2014) (9)
- Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance. (2011) (9)
- KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma (2021) (8)
- Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers (2019) (8)
- Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials. (2013) (8)
- OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers (2017) (8)
- Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer. (2017) (8)
- Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. (2010) (8)
- 9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC) (2011) (8)
- Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers. (2017) (7)
- Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib (2021) (7)
- Molecular determinants of response and resistance to anti-PD-(L)1 blockade in patients with NSCLC profiled with targeted next-generation sequencing (NGS). (2017) (7)
- Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). (2009) (7)
- Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment (2021) (7)
- Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. (2022) (7)
- EGFR mutations in men and cigarette smokers with lung adenocarcinoma. (2010) (7)
- Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. (2012) (7)
- Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor (2021) (7)
- Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. (2014) (7)
- Phase II study of cixutumumab (IMC-A12) in thymic malignancies. (2012) (6)
- YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. (2017) (6)
- OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy (2021) (6)
- CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. (2021) (6)
- A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. (2009) (6)
- Malignant pleural mesothelioma. (2015) (6)
- A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). (2012) (6)
- KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation. (2022) (6)
- Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma (2008) (6)
- Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC. (2017) (6)
- Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay. (2015) (6)
- Thymic malignancies. (2010) (6)
- NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
- Investigation of patterns of nodal metastases in BRAF mutant lung cancer. (2017) (6)
- Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma. (2010) (6)
- A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). (2012) (5)
- Clinician Perspectives on Current Issues in Lung Cancer Drug Development (2016) (5)
- Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC). (2013) (5)
- Lung cancer in 'Never-smokers': molecular factors trump risk factors. (2010) (5)
- Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer (2018) (5)
- Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important? (2005) (5)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers (2019) (4)
- Defining the immunologic phenotype of thymic epithelial tumors. (2015) (4)
- Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung (2005) (4)
- P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (2021) (4)
- Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC) (2013) (4)
- A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer (2007) (4)
- Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. (2020) (4)
- Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC (2022) (4)
- Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers (2021) (4)
- Management of thymoma‐associated pure red cell aplasia: A novel use of blood substitute HBOC‐201 in a Jehovah’s Witness (2019) (4)
- Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib (2005) (4)
- Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001. (2019) (4)
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2 (2022) (3)
- P3.02b-115 Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib (2017) (3)
- Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers. (2018) (3)
- Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy?: Metastatic Non-Small Cell Lung Cancer (2014) (3)
- Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer (2020) (3)
- Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. (2021) (3)
- Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer. (2021) (3)
- Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. (2017) (3)
- Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer. (2022) (3)
- 988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP) (2022) (3)
- P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions (2019) (3)
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2 (2022) (3)
- Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? (2014) (3)
- Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: The Memorial Sloan-Kettering experience (2008) (3)
- 1463OPROSPECTIVE MOLECULAR EVALUATION OF SMALL CELL LUNG CANCER (SCLC) UTILIZING THE COMPREHENSIVE MUTATION ANALYSIS PROGRAM (MAP) AT MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC). (2014) (2)
- Pulse-continuous dose erlotinib as initial targeted therapy for patients with EGFR-mutant lung cancers with untreated brain metastases. (2017) (2)
- Multidisciplinary management of thymic carcinoma. (2012) (2)
- Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer. (2020) (2)
- Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers. (2012) (2)
- 1299PCLINICAL ACTIVITY OF CRIZOTINIB IN ROS1-REARRANGED NON-SMALL CELL LUNG CANCER. (2014) (2)
- MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion-positive lung cancer. (2022) (2)
- Small cell lung cancer (SCLC) among patients who are never smokers. (2013) (2)
- Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA. (2011) (2)
- P1.14-50 A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma (2019) (2)
- Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC). (2011) (2)
- Beyond "second-line" in non-small cell lung cancer: therapy and supportive care. (2015) (2)
- Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies. (2018) (2)
- HER2 Amplifi cation: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR (2012) (2)
- Abstract CT025: Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC) (2020) (2)
- Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer. (2022) (2)
- Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer. (2021) (2)
- Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. (2010) (2)
- 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial. (2012) (2)
- Type A thymoma presenting with bone metastasis (2018) (2)
- Abstract 1095: Comprehensive pan-cancer analyses of RAS genomic diversity (2020) (2)
- Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer (2022) (2)
- Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort (2021) (2)
- Serplulimab With Chemotherapy in Extensive-Stage SCLC. (2022) (2)
- Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (2)
- Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. (2016) (2)
- Acquired BRAF fusions as a mechanism of resistance to EGFR therapy. (2018) (2)
- Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations (2021) (2)
- Pan-cancer evaluation of homologous repair deficiency somatic mutations and response to first-line anti-neoplastic therapy. (2021) (1)
- 1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy (2021) (1)
- Reply to E.M. Gilles (2012) (1)
- Reproducibility of computed tomography (CT) measurements of lung cancer (2008) (1)
- Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. (2019) (1)
- Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS). (2015) (1)
- A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC). (2013) (1)
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) (1)
- 1142PDLARGE CELL NEUROENDOCRINE CARCINOMAS (LCNEC) OF THE LUNG: PATHOLOGIC FEATURES, TREATMENT AND OUTCOMES. (2014) (1)
- Who should receive EGFR tyrosine-kinase inhibitors? (2012) (1)
- Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung (2005) (1)
- Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y). (2018) (1)
- YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics (2018) (1)
- Reply to M.C. Garassino et al (2011) (1)
- YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs). (2020) (1)
- A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach (2022) (1)
- The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. (2017) (1)
- One committee to review it all: A single, multi-disciplinary COVID-19 research committee (2022) (1)
- OA11.05 A Phase 2 Study of Cabozantinib for Patients with Advanced RET-Rearranged Lung Cancers (2017) (1)
- 1218P Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy (2021) (1)
- Prognostic implications of mutations in the epidermal growth factor receptor (EGFR) and KRAS among never-smokers with adenocarcinoma of the lung. (2010) (1)
- Predictive Biomarkers and Personalized Medicine ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1 , 683 Patients with Non – Small Cell Lung Cancer (2013) (1)
- Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program at Memorial Sloan-Kettering Cancer Center (MSKCC). (2013) (1)
- Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. (2014) (1)
- Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? (2014) (1)
- Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation?: Metastatic Non-Small Cell Lung Cancer (2014) (1)
- Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation (2022) (1)
- NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology (2014) (1)
- Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung. (2011) (1)
- EGFR and KRAS mutation status of lung adenocarcinomas in African Americans. (2009) (1)
- A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment (2012) (1)
- Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers (2022) (1)
- Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis. (2021) (1)
- Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. (2022) (1)
- Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs. (2019) (1)
- Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD. (2022) (1)
- Abstract B012: Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in preliminary clinical analyses (2023) (0)
- OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001 (2017) (0)
- Cancer Growth Factor Receptor ( EGFR ) Exon 20 Insertion Mutations in Lung Structural , Biochemical , and Clinical Characterization of Epidermal (2013) (0)
- Stage at diagnosis as a prognostic marker for patients with KRAS-mutant metastatic lung adenocarcinomas. (2014) (0)
- Abstract 2620: Ignoring left truncation in overall survival within real-world genomic-phenomic data leads to inflated survival estimates (2021) (0)
- Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas. (2019) (0)
- Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection. (2016) (0)
- Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers. (2018) (0)
- 1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer (2022) (0)
- P1.14-12 A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC (2019) (0)
- Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance inROS1fusion positive lung cancers (2021) (0)
- P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition (2018) (0)
- Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers (2022) (0)
- P1.14-06 Tissue-Based Molecular and Histologic Landscape of Acquired Resistance to Osimertinib in Patients with EGFR-Mutant Lung Cancers (2019) (0)
- Characteristics of NSCLCs harboring NRAS mutations. (2012) (0)
- NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors (2006) (0)
- Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (0)
- IS7. lung cancer (2012) (0)
- Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers (2020) (0)
- A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ) (2012) (0)
- Brain Metastases in EGFR-Mutated Lung Cancer: Is Radiation Therapy Necessary? (2013) (0)
- Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas. (2018) (0)
- Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer. (2022) (0)
- Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer. (2022) (0)
- Abstract 4259: Identification of anti-neoplastic therapy given before initial visit at a referral center using natural language processing applied to medical oncology initial consultation notes (2023) (0)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) (0)
- Genomic mapping of metastatic organotropism in lung adenocarcinoma. (2023) (0)
- Comparison of CISH and FISH for detection of EGFR copy number in lung adenocarcinoma and correlation with EGFR and KRAS mutation status and EGFR immunoreactivity (2008) (0)
- Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data (2022) (0)
- Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer (2018) (0)
- Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. (2023) (0)
- Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib (2008) (0)
- Use of an Internet-based protocol to collect clinical information and blood from patients with lung cancer who never smoked cigarettes. (2009) (0)
- Abstract 1784: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations (2010) (0)
- Abstract 610: Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing (2015) (0)
- Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (0)
- OA 03.03 Phase II Trial of Cetuximab and Chemotherapy Followed by Surgical Resection for Locally Advanced Thymoma (2017) (0)
- A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer (2020) (0)
- Concurrent molecular alterations in KRAS-mutant lung adenocarcinomas and effects on overall survival. (2014) (0)
- Malignant Pleural MesotheliomaPractice Guidelines in Oncology (2012) (0)
- Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer (2022) (0)
- Progression-free survival estimates in non-small cell lung cancer when RECIST is unavailable: Project GENIE’s integration of genomic, therapeutic and phenomic data. (2020) (0)
- 474P Genomic characterization and clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) with peritoneal metastases (PM) in AACR project GENIE (2021) (0)
- Sequencing Therapy for Patients With Lung Cancer (2020) (0)
- 1270P Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes (2021) (0)
- CMET-08. PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTATIC ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) (2017) (0)
- Abstract B31: Single-agent pemetrexed in patients with ALK-positive NSCLC: A retrospective analysis of investigator-reported outcomes (2012) (0)
- Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C–mutated metastatic colorectal cancer in AACR Project GENIE. (2023) (0)
- Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis. (2022) (0)
- Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival (2023) (0)
- Clinical characteristics and outcomes for patients with thymic carcinoma: Evaluation of Masaoka staging. (2014) (0)
- Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer (2022) (0)
- ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus (2007) (0)
- Liquid biopsy in the clinic: A prospective study of plasma circulating tumor DNA (ctDNA) next generation sequencing (NGS) in patients with advanced non-small cell lung cancers to match targeted therapy. (2017) (0)
- Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research (2021) (0)
- Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration (2020) (0)
- Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
- Quantitating pathologic response to neoadjuvant chemotherapy in KRAS-mutated versus nonmutated lung cancers. (2012) (0)
- Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study (2023) (0)
- Smoking history and frequency of somatic KRAS mutations in adenocarcinoma of the lung (2007) (0)
- Abstract 4260: Understanding genomic and social determinants of cancer immunotherapy outcome across ancestry (2023) (0)
- thresholds A rheostatic mechanism for T-cell inhibition based on elevation of activation (2010) (0)
- A Phase IB Dose-Escalation Study of the HSP90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (2014) (0)
- Vascular endothelial growth factor trap in non-small cell lung cancer. Discussion (2007) (0)
- 8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency (2023) (0)
- The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma (2021) (0)
- Brief report: Combination of Osimertinib and Dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas. (2023) (0)
- Abstract 5185: Intratumoral Escherichia is associated with response to single-agent immune checkpoint inhibition in patients with advanced non-small cell lung cancer (2023) (0)
- Abstract 102: Clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS p.G12C-mutated metastatic non-small cell lung cancer (NSCLC) in the AACR Project GENIE database (2021) (0)
- P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis (2017) (0)
- O1–133CRIZOTINIB VS. PEMETREXED OR DOCETAXEL IN ADVANCED ALK+ NON-SMALL CELL LUNG CANCER: SUBGROUP ANALYSIS IN PROFILE 1007 (2013) (0)
- Bronchioloalveolar Carcinoma of the Lung (2006) (0)
- Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer (2012) (0)
- Advanced age is associated with lack of administration of adjuvant chemotherapy for completely resected stage IB-III non-small cell lung cancer (NSCLC): PD4-2-8 (2007) (0)
- OA 10.03 Liquid Biopsy in the Lung Cancer Clinic: A Prospective Study of Plasma DNA next Generation Sequencing to Guide Matched Therapy (2017) (0)
- Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal masses. (2023) (0)
- Abstract 2506:Smarca4inactivation promotes lineage-specific transformation and early metastatic features in the lung (2021) (0)
- SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors (2022) (0)
- PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators: Topic: Medical Oncology (2017) (0)
- Abstract 2619: Defining real-world recurrence in the AACR Project GENIE Biopharma Collaborative Data (2021) (0)
- Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]. (2021) (0)
- Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study (2022) (0)
- Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors. (2011) (0)
- PD4-2-8: Advanced age is associated with lack of administration of adjuvant chemotherapy for completely resected stage IB-III non-small cell lung cancer (NSCLC) (2007) (0)
- AB009. OS02.03. Phase II trial of cetuximab and chemotherapy followed by surgical resection for locally advanced thymoma (2017) (0)
- 1288PA PHASE IB DOSE-ESCALATION STUDY OF THE HSP90 INHIBITOR SNX-5422 AND ERLOTINIB IN PATIENTS WITH EGFR-MUTANT LUNG CANCER AND ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS. (2014) (0)
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. (2023) (0)
- P1.01-75 Utility of cfDNA Testing for Acquired Resistance: The Memorial Sloan Kettering Experience with Plasma EGFR T790M Clinical Testing (2018) (0)
- Next generation sequencing (NGS) in resectable non-small cell lung cancer (NSCLC): Therapeutic implications. (2016) (0)
- Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas (2022) (0)
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
- Lung cancers with mutations in EGFR exon 18: Molecular characterization and clinical outcomes in response to tyrosine kinase inhibitors. (2017) (0)
- Clinicopathologic and mutational landscape of BRAFV600E-mutant non–small cell lung carcinoma. (2022) (0)
- Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer (2020) (0)
- EP08.02-171 PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC) (2022) (0)
- AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy (2022) (0)
- P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles (2019) (0)
- Toward Sites of TCR Engagement Focal Localization of Placental Protein 14 (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gregory J Riely?
Gregory J Riely is affiliated with the following schools:
